Title:
PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF INFLAMMATORY BOWEL DISEASE COMPRISING GLYCOGEN PHOSPHORYLASE (PYGL) INHIBITOR AS ACTIVE INGREDIENT
Document Type and Number:
WIPO Patent Application WO/2024/085698
Kind Code:
A1
Abstract:
The present invention provides a pharmaceutical composition for the prevention or treatment of inflammatory bowel disease, comprising a glycogen phosphorylase (PYGL) inhibitor as an active ingredient, and a method for screening for a material for the prevention or treatment of inflammatory bowel disease. By using the pharmaceutical composition for the prevention or treatment of inflammatory bowel disease, comprising a PYGL inhibitor as an active ingredient, according to the present invention, inflammatory bowel disease such as ulcerative colitis can be prevented or treated. Also, through the method for screening for a material for the prevention or treatment of inflammatory bowel disease, according to the present invention, a material that reduces PYGL activity can be determined as a candidate material for the prevention or treatment of inflammatory bowel disease.
Inventors:
LIM DONG CHUL (KR)
PARK HEE DONG (KR)
KIM TAE HUN (KR)
RYU JAEYOON (KR)
PARK HEE DONG (KR)
KIM TAE HUN (KR)
RYU JAEYOON (KR)
Application Number:
PCT/KR2023/016299
Publication Date:
April 25, 2024
Filing Date:
October 19, 2023
Export Citation:
Assignee:
INNOVO THERAPEUTICS INC (KR)
International Classes:
A61K31/4439; A61K31/192; A61K31/404; A61K31/4418; A61K31/4545; A61P1/00; A61P1/04; A61P29/00; G01N33/50
Domestic Patent References:
| WO2019087129A1 | 2019-05-09 |
Foreign References:
| KR20210035454A | 2021-04-01 |
Other References:
LEI ZHANG: "Benzamide derivatives as dual-action hypoglycemic agents that inhibit glycogen phosphorylase and activate glucokinase", BIOORGANIC & MEDICINAL CHEMISTRY, ELSEVIER, AMSTERDAM, NL, vol. 17, no. 20, 1 October 2009 (2009-10-01), AMSTERDAM, NL, pages 7301 - 7312, XP093160325, ISSN: 0968-0896, DOI: 10.1016/j.bmc.2009.08.045
OLIVER ANDERKA: "Thermodynamic Characterization of Allosteric Glycogen Phosphorylase Inhibitors", BIOCHEMISTRY, AMERICAN CHEMICAL SOCIETY, vol. 47, no. 16, 1 April 2008 (2008-04-01), pages 4683 - 4691, XP093160330, ISSN: 0006-2960, DOI: 10.1021/bi702397d
QIAN ZHAN: "Glycogen storage disease type VI with a novel PYGL mutation : Two case reports and literature review", MEDICINE, WILLIAMS AND WILKINS, BALTIMORE., US, vol. 100, no. 16, US , pages e25520, XP093160334, ISSN: 0025-7974, DOI: 10.1097/MD.0000000000025520
OLIVER ANDERKA: "Thermodynamic Characterization of Allosteric Glycogen Phosphorylase Inhibitors", BIOCHEMISTRY, AMERICAN CHEMICAL SOCIETY, vol. 47, no. 16, 1 April 2008 (2008-04-01), pages 4683 - 4691, XP093160330, ISSN: 0006-2960, DOI: 10.1021/bi702397d
QIAN ZHAN: "Glycogen storage disease type VI with a novel PYGL mutation : Two case reports and literature review", MEDICINE, WILLIAMS AND WILKINS, BALTIMORE., US, vol. 100, no. 16, US , pages e25520, XP093160334, ISSN: 0025-7974, DOI: 10.1097/MD.0000000000025520
Attorney, Agent or Firm:
PHIL & ONZI INT'L PATENT & LAW FIRM (KR)
Download PDF:
Previous Patent: STABLE ANTIBODY COMPOSITION
Next Patent: COMPOUND FOR SHP2 PROTEIN DEGRADATION AND MEDICAL USES THEREOF
Next Patent: COMPOUND FOR SHP2 PROTEIN DEGRADATION AND MEDICAL USES THEREOF